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Background: A retrospective review of patients treated with Occipital Nerve Stimulation (ONS) at two large tertiary
referral centres has been audited in order to optimise future treatment pathways.
Methods: Patient’s medical records were retrospectively reviewed, and each patient was contacted by a trained
headache expert to confirm clinical diagnosis and system efficacy. Results were compared to reported outcomes in
current literature on ONS for primary headaches.
Results: Twenty-five patients underwent a trial of ONS between January 2007 and December 2012, and 23 patients
went on to have permanent implantation of ONS. All 23 patients reached one-year follow/up, and 14 of them
(61%) exceeded two years of follow-up. Seventeen of the 23 had refractory chronic migraine (rCM), and 3 refractory
occipital neuralgia (ON). 11 of the 19 rCM patients had been referred with an incorrect headache diagnosis. Nine of
the rCM patients (53%) reported 50% or more reduction in headache pain intensity and or frequency at long term
follow-up (11–77 months). All 3 ON patients reported more than 50% reduction in pain intensity and/or frequency
at 28–31 months. Ten (43%) subjects underwent surgical revision after an average of 11 ± 7 months from
permanent implantation - in 90% of cases due to lead problems. Seven patients attended a specifically designed,
multi-disciplinary, two-week pre-implant programme and showed improved scores across all measured
psychological and functional parameters independent of response to subsequent ONS.
Conclusions: Our retrospective review: 1) confirms the long-term ONS success rate in refractory chronic headaches,
consistent with previously published studies; 2) suggests that some headaches types may respond better to ONS
than others (ON vs CM); 3) calls into question the role of trial stimulation in ONS; 4) confirms the high rate of
complications related to the equipment not originally designed for ONS; 5) emphasises the need for specialist
multidisciplinary care in these patients.
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Chronic Daily Headache (CDH) is an umbrella term for
headache disorders with a high rate of reoccurrence (15
or more days per month for 3 consecutive months).
CDH represents a major worldwide health problem as
affects 3–5% of adults [1-3] who experience substantial
disability.
Chronic migraine (CM), the most prevalent form of
CDH, is defined as headache occurring more than 15 days/
month for at least 3 consecutive months, with headache
having the clinical features of migraine without aura
for at least 8 days per month [4]. Recently published
results from the American Migraine Prevalence and
Prevention Study (AMPP) found the prevalence of CM
in the United States is approximately 1% [5]. The World
Health Organization recognizes migraine as a major
public health problem, ranking it at 7th place among all
worldwide diseases leading to disability [6]. Compared
to episodic migraine, CM is associated with higher
disability, inferior quality of life and greater health
resource utilization [7].
Despite substantial advances in migraine therapy [8],
some individuals with chronic migraine are either resist-
ant or intolerant to guideline-based treatments [9]. This
subset of patients requires the development of further
treatments and in recent years peripheral neuromodu-
lation, in the form of occipital nerve stimulation (ONS),
has emerged as an option for this subset of patients
[8,10]. Several published small retrospective studies
reported promising safety and efficacy data for ONS in
primary headaches.
Open label studies in trigeminal autonomic cepha-
lalgias have shown significant, long-term benefit in 67%
of refractory chronic cluster headache patients [10] and
in 89% of refractory SUNCT and SUNA (short-lasting
neuralgiform headache attacks with conjunctival injec-
tion and tearing/autonomic symptoms) patients [11].
Encouraging results in refractory chronic migraine pa-
tients led to three, commercially funded, multi-centre
randomized trials [12,13]. The benefits shown in these
trials were less dramatic than hoped for, however the
studies have been criticised for methodological weak-
nesses, unmitigated placebo effect, and a high rate of
surgical complications, which may have obscured the
full beneficial effect of ONS. Limited data on relevant
endpoints was available at the time of studies’ design
and poor endpoint choice may have masked the true
efficacy of ONS [13].
Thus, the literature leaves many questions unanswered
about the role for ONS in chronic daily headache. Our
institutions are large, tertiary neuromodulation centers
with a special interest in headaches. We agreed to pool
resources and retrospectively audit our own data on
ONS for CDH to help guide us on future clinicalindications for ONS, identify areas for improved clinical
practice, technical practice and data collection.
This paper reports the results of our audit and relates
these to the literature. We discuss the importance of
specialists within a multidisciplinary treatment team,
question the use of temporary trials to select ONS-
responders, and look at surgical strategies to limit
hardware-related complications.
Methods
Two large tertiary neuromodulation centers (Guy’s &
St Thomas NHS Trust, London, United Kingdom and
Sapienza University at Sant’Andrea Hospital, Rome,
Italy) retrospectively audited outcomes of patients receiv-
ing ONS from the previous 6 years. The audit results
were analyzed with reference to available literature on
ONS for CDH. Ethics committee approval was not re-
quired for this audit.
Audit process
All patients receiving a trial of ONS in the last 6 years
at both institutions were included in the audit. Patient
demographics, headache phenotype and technical details
of the surgical procedure(s) were collected from patient
medical records. Telephone reviews (up to three per
patient) were performed by one headache specialist for
each site (GL and PM) to confirm data accuracy, system
efficacy and, when needed, to re-code patients’ diagnosis
according to the ICHD-II classification [14].
ONS indication
At both sites, the indication for ONS was refractory
chronic headaches. Patients had failed to significantly
improve after adequate trials of four classes of prevent-
ive medicines and three classes of acute drugs with
established efficacy [15].
ONS candidates were advised not to proceed with
surgery when psychological evaluation identified condi-
tions which could be aggravated by the treatment or
cause confusion in interpreting clinical results (including,
but not limited to, intractable epilepsy, active major
depression, psychosis, somatoform disorder, severe per-
sonality disorder).
Surgical procedure
The ONS surgical procedure was performed by four
different operators, with equipment and surgical tech-
nique (particularly lead insertion and anchoring) vary-
ing between operators and over time (Figure 1). All
patients underwent a trial of therapy. One or two per-
cutaneous lead(s) were inserted under sedation in the
subcutaneous tissue above the peripheral branches of
the occipital nerves at approximately C1 level, and left
in place for 7 – 10 days to evaluate the efficacy and
Figure 1 Example of 3 different approaches for ONS. From left to right, 1) single lead monolateral ONS; 2) dual lead, bilateral ONS; 3) single
lead bilateral ONS.
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trial was “successful”, i.e. the patient reported at least
50% decrease in headache intensity and/or frequency
associated with a decrease headache medication use, a
permanent implant was then performed under general
anaesthesia. Leads were implanted as in the trial, but
this time they were anchored to fascia, tunnelled, and
connected to an IPG sited in a subcutaneous abdominal
pocket. The practice of leaving stress relief loops in
each of the subcutaneous incisions was implemented in
some of the subjects implanted after the technique was
widely published as part of large multi-centre study [16].
Outcome
The patients were treated by different physicians in dif-
ferent centres across a 6-year timeframe and a variety of
outcomes were measured for both trial and full implant
efficacy. To homogenously evaluate ONS outcomes and
be consistent in neuromodulation trial evaluation, we
decided a patient implanted with a permanent ONS
system would be considered a “success” if a sustained
decrease of at least 50% in headache intensity and/or
frequency was reported by the patient during the tele-
phone review. Those patients with whom we did not
make telephone contact were excluded from the out-
come analysis regardless of the information reported in
their medical notes.
Cognitive Behavioural Therapy (CBT) based implant
preparation
In one of the two centres involved in the study (GSTT),
some patients were required to attend a pre-implant
programme (PIP) before proceeding to the trial stage.The PIP involves groups of up to 11 patients engaging
in 7–9 days activity spread over two weeks. Physicians,
psychologists, physiotherapists, nurses and occupational
therapists provide a variety of broadly CBT based inter-
ventions, which explicitly seek to reduce emotional dis-
tress [17] and improve social and physical functioning
[18]. This is done by addressing an individual’s in-
terpretation, evaluations and beliefs about their health
condition [19].
Several outcome measures are routinely collected dur-
ing the course of the PIP, many of those reflecting the
IMMPACT recommendations [20] and measuring pain-
related disability as a primary outcome variable. Among
those: 1) The Pain Disability Index (PDI), which measures
the extent to which chronic pain interferes with daily
activities [21]; 2) the Beck Depression Index (BDI), which
measures the severity of self-reported depressive symp-
toms [22]; 3) the Pain Self Efficacy Questionnaire (PSEQ),
which evaluates how confident patients feel about carry
out a variety of tasks despite their pain [23]; 4) the Pain
Catastrophizing Scale (PCS), which measures the extent
of catastrophising thoughts and feelings associated with
pain [24]; 5) the Tampa Scale of Kinesiophobia (TSK),
which is a measure of pain-related fear of movement or
re-injury [25].
Patients at GSTT who did not do a PIP attended a
“Technology Day” instead. This examines patient expec-
tations of treatment with a psychologist, includes infor-
mation and question and answer sessions given by a
physiotherapist and nurse on the stimulator itself and
briefly educates on chronic pain and ways of managing
this more effectively. Formal psychological data is not
gathered, and CBT-based interventions are not provided.
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Descriptive statistics has been used to interpret data as
appropriate, and data were presented mean ± standard
deviation if not stated otherwise. Wilcoxon signed-rank
non-parametric test has been used to compare psycho-
logical variables in the small subgroup of patients who
attended the PIP. Significance level was set at α = 0.05.Results
Twenty-five patients underwent a trial of ONS between
January 2007 and December 2012 (Male/Female: 7/18;
Average age: 49 ± 14 years) (Table 1). Only three patients
did not report enough relief during the period of percu-
taneous stimulation to consider the trial a successful
(success rate = 88%), but one patient still requested and
received a permanent system. Therefore, 23 patients whoTable 1 Diagnoses, laterality and site of the pain of the samp
stimulation
Diagnosis
Sex Definitive Preliminary Trigger
1 F CM ON No
2* F CM CM No
3 F CM ON Yes (S)
4 F CM CDH Yes (S)
5 F CM Migraine No
6* M CM ON No
7 F CM ON Yes (T)
8 F IIH ON No
9* M CM ON No
10 M ON ON No
11 F ON ON No
12 F CH CH No
13 M CM ON No
14 F ON ON No
15 F CM ON No
16 M CM Migraine No
17 M CM ON No
18 F CM ON No
19 F CM ON Yes (T)
20 M Cerv.H. ON Yes (T)
21 F CM ON Yes (T)
22 F CM CM N/A
23 F CM CM N/A
24 F CM CM N/A
25 F CM CM N/A
CM chronic migraine, IIH idiopathic intracranial hypertension, ON occipital neuralgia
Headache, N/A data not available, T Post-traumatic, onset of the headache within a
within a week from a scheduled or un-scheduled surgery; * Pts considered to havereceived a permanent ONS system were included in the
following analysis (Table 2).
All patients reached one-year follow-up, and 14 of
them (61%) exceeded two years of follow-up (Average
36 ± 23 months, median 28 months). Ten (43%) subjects
underwent at least one surgical revision after an average
of 11 ± 7 months from permanent implantation, and 90%
of the revision surgeries were needed because of problems
with leads. Battery replacements were not considered as
surgical revisions, unless battery depletion was caused by
high lead impedances. Nine patients required at least one
surgical revision to replace the stimulating lead because of
displacement (3), high impedances (2), local infection/skin
erosion (2) or painful paresthesia (2). Eight subjects (35%)
had their system removed after an average implant time
of 30 ± 21 months (range 2 – 61 months), either for in-
efficacy (4/23), infection (1/23) or both (2/23). Onele of headache patients trialled with Occipital nerve
Pain distribution
Bilateral Length Area of origin Radiation
Y 2 ys Occipital Vertex
Y 16 ys Neck/Occipital Occipital
Y 6 ys Occipital Forehead
Y N/A Ear Ear/Face
N 15 ys Eye Eye
N 17 ys Eye Forehead
Y 1 ys Occipital Vertex
Y 2 ys Occipital Holocranic
Y 8 ys Neck Occipital
Y 10 ys Occipital Holocranic
Y 4 ys Neck/Occipital Vertex
N 5 ys Occipital Eye
N N/A N/A N/A
Y 3 ys Occipital Shoulders
Y 15 ys Neck Temple
N 3 ys Occipital Hemicranium
Y 15 ys Neck/Occipital Forehead
Y 15 ys Neck/Occipital Eye
Y 19 ys Occipital Forehead
Y 10 ys Occipital Forehead
N 3 ys Neck Vertex/Eye
N N/A Temple Temple
N N/A Temple Forehead
N N/A Eye Hemicranium
Y N/A Forehead Holocranic
, CH Cluster Headache, CDH chronic daily headache, Cerv.H Cervicogenic
week following a head/neck injury, S Post-Surgical, onset of the headache
failed the ONS trial.
Table 2 Paraesthesia coverage, types of implants, outcome, complications and removal rate of patients implanted with occipital nerve stimulation
Diagnosis Side
shift
Origin
of pain
Implant
success
Lead(s) Paraesthesia
coverage
Last
Fw/up
Revision surgery Time to
revision
Removal Time to
removal
1 CM Y Occipital No 1 Quadripolar Good 77 – – – –
2 CM Y Neck/ Occipital No 1 Quadripolar Excellent – – – Painful paraesthesia - inefficacy 10
3 CM Y Occipital Yes (100%) 2 Quadripolar Good 71 Battery site hyperalgesia 2 – –
4 CM Y Ear Yes (90%) 2 Octopolar Moderate – – – Granuloma and skin erosion 29
5 CM N Eye Yes (100%) 2 Octopolar Moderate 42 – – – –
6 CM Y Occipital Yes (90%) 2 Octopolar Excellent 18 Infection lead (×2) 11 – –
7 IIH Y Occipital Yes (100%) 2 Octopolar Excellent 21 – – – –
8 ON Y Occipital Yes (100%) 1 Quadripolar Excellent 28 – – – –
9 ON Y Neck/ Occipital Yes (70%) N/A Excellent 31 Tilted IPG N/A – –
10 CH N Occipital Yes (50%) N/A N/A 28 Lead replacement (High Imp.) 24 – –
11 CM N N/A No (<50%) 2 Octopolar Poor – – – Inefficacy 54
12 ON Y Occipital Yes (50%) N/A Good 28 – – – –
13 CM Y Neck Yes (100%) N/A Excellent 48 Skin erosion (×3) N/A – –
14 CM N Occipital No N/A N/A – – – Inefficacy and implant site infection 2
15 CM Y Neck/ Occipital No 2 Octopolar Excellent – 1st: painful paraesthesia; 2nd: SO lead added 12 Inefficacy 35
16 CM Y Neck/ Occipital No 1 Octopolar Excellent 79 – – – –
17 CM Y Occipital No 1 Octopolar Excellent – Lead migration 8 Inefficacy 20
18 Cerv.H. Y Occipital No 2 Octopolar Good – Several granulomas, lead breakage N/A Inefficacy and implant site infection 61
19 CM N Neck Yes (50%) 2 Octopolar Moderate 31 – – – –
20 CM N Temple Yes (70%) 2 Quadripolar Poor 13 – – – –
21 CM N Temple Yes (50%) 2 Quadripolar Poor 11 Lead and IPG replaced (High Imp.)
SO lead added
7 – –
22 CM N Eye Yes (50%) 2 Quadripolar Poor 12 – – – –
23 CM Y Forehead No 2 Quadripolar Poor – Lead migration – Pt request despite effective 12
FI full implant, IPG implanted pulse generator, N/A data not available, SO supraorbital, Paresthesia Coverage % of original painful area covered by paresthesia. Last follow/up (Fw/up), Time to Revision and Time to
removal all expressed in months.
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logical reasons despite receiving significant benefit
from it.
All 25 patients were reviewed by the headache spe-
cialists during the telephone interview. Nineteen patients
(76%) were diagnosed with refractory chronic migraine
(rCM), 3 (12%) with refractory occipital neuralgia, 1
(4%) with refractory chronic cluster headache and 2
(8%) with other forms of chronic headache (see Table 1).
Interestingly, only 7 of the rCM patients were referred
with this diagnosis for ONS, while 11/19 were wrongly
labelled as occipital neuralgia and 1/19 as chronic
headache refractory to medical treatment.
Seventeen patients with a diagnosis of rCM received a
permanent ONS system, and all but three had a success-
ful trial before the implant (84% success rate). Two of
the subjects with an unsuccessful trial did not proceed
to the full implant. One patient, against medical recom-
mendation, decided to undergo full implantation despite
limited benefit from the trial and reported a mild benefit
(< 50% relief ) after 5 years of follow-up.
Nine subjects (53%) reported significant pain relief
(> 50% relief in attacks’ intensity and/or frequency)
after an average follow-up of 40 ± 27 months (range
11–77 months).
In 5/17 (4 of which with sustained pain relief ), mi-
graine attacks originated in the trigeminal nerve distri-
bution, while 11/17 patients had their original pain in
the occipital area and of those, 5 reported significant re-
lief over time. It should be noted that in most patients
headache pain radiates in both territories as the migraine
attacks progress.
Seven of the eight patients who had their system
removed were classified as rCM. Five were removed for
inefficacy (despite a successful initial percutaneous trial),
and one for acquired infection not responding to anti-
biotic therapy.
Three subjects were classified as refractory occipital
neuralgia, with a history of tenderness over the occipi-
tal area and temporary pain relief following at least one
occipital nerve block with local anaesthetic and/or ste-
roids. All had a successful trial of stimulation and all of
them (100%) report significant relief (well over 50%
reduction in severity and frequency) after 28, 28 and
31 months of follow/up from the permanent insertion
of the ONS system, respectively.
Seven patients (6 rCM and 1 ON) attended a specific-
ally designed, multi-disciplinary, two-week pre-implant
programme (PIP). Attending the programme was associ-
ated with improved scores across all measured psycho-
logical and functional parameters. Statistically significant
improvement occurred in the BDI scores, with a mean
decrease of 7.4 (95% CI: 2.3 – 12.5), and in the TSK
scores, with an average decrease of 8 points (95% CI:2.2 – 13.8). The analysed population was very small
and differences observed between responders and non-
responders did not reach statistical significance. How-
ever, long-term responders seemed to have higher values
of PCS scores before the PIP than non-responders, and
were able to decrease their BDI values during the course
more than those who failed ONS treatment.
Discussion
ONS is a promising treatment for some refractory pri-
mary headaches, but its role needs further definition.
We have presented 6 years ONS experience in two
European neuromodulation centres closely working as
twin teams with tertiary headache centres. Our data is
consistent with published studies that suggest ONS has
a place in the management of patients with refractory
chronic migraine and with refractory occipital neuralgia -
but that much work needs to be done to refine patient
selection and optimise the treatment. Our analysis has
highlighted important specific areas to focus on in the
future clinical and research use of ONS.
The concept of a multidisciplinary approach to
refractory headaches
In order to face the clinical challenge of refractory
chronic headaches there is a need of at least three
different specialists to be involved in the selection of
refractory headaches patients as potential candidate for
ONS: a referring headache specialist, a pain physician
with expertise in neuromodulation and a psychologist
with expertise in chronic pain. The presence of a head-
ache specialist with expertise in ICDH-II diagnostic
classes must be considered mandatory in future. Many
patients included in our analyzed cohort were reclassi-
fied when reviewed by a trained headache specialist:
only 25% of the patients were correctly labelled as CM
at the time of the referral, and only 19% of the subjects
originally labelled as occipital neuralgia fulfilled the
ICDH-II criteria for this diagnosis. Our results are in
line with previous ONS retrospective analysis, where
patients reviewed by an headache specialist were often
re-coded [26]. As evidenced by the difference between
long-term efficacy (53% CM vs 100% ON) and system
removal rates (7 patients with CM vs 0 with ON) in
our series, correct diagnosis is essential for scientific
and economic evaluation of ONS.
Inappropriate use of the words “refractory” and “intract-
able” might also led healthcare professionals to improperly
label patients as “refractory” even if they have not been
on an appropriate trial of acute treatments or have never
been tried on a preventive medication at an adequate
doses for a reasonable period of time [9,15]. Efficacy of
onabotulinumtoxinA as a preventive treatment of chronic
migraine has been shown in the PREEMPT studies [27]
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therapies to be tried before labeling a migraine patient
as refractory and offering them invasive treatments. 15
of the patients included in our series had their system
implanted before the PREEMPT publication (and there-
fore did not receive onabotulinumtoxinA treatment), it
is possible that some of them might have responded to
onabotulinumtoxinA treatment without the need of an
ONS implant.
Patients with chronic migraine experience the same
complex spectrum of biopsychosocial problems seen in
other chronic pain conditions [28,29]. Anxiety, depres-
sion, sleep interference, employment interference, rela-
tionship interference and decreased physical and social
activity are important factors in overall morbidity and
should be assessed and addressed. The GSTT subgroup
in our data who participated in a pre-implant pain
management approach (PIP) experienced improvement
across all measured psychosocial domains leading to
improved quality of life and health outcomes. However,
in our series more patients had a successful implant
who did not have a PIP (7/9 vs 3/7), suggesting that
while the PIP is efficacious itself, in its current form it
may not provide the best preparation of patients for an
implant. The current PIP focuses on encouraging pa-
tients to manage their pain and maximise activity and
does not focus on patient selection for ONS.
Careful assessment of psychosocial domains should
lead to improved ONS patient selection and outcomes -
this is widely observed recognised in other neuromo-
dulation areas [19,30,31]. Pain duration, psychological
distress, pain catastrophising, psychiatric conditions in-
cluding personality disorders, history of abuse, and sig-
nificant cognitive deficits are associated with poor
outcomes from pain treatments in general [32]. Depres-
sion has been identified as the single most important
factor predictive of efficacious Spinal Cord Stimulation
[33], and other factors including somatization, anxiety,
poor coping also predict poor response [34]. Reports
on ONS to date have focussed on technical details and
patient outcomes have centred on pain scores as a
measure of patient benefit [10] and there is an absence
of literature looking at patients’ psychosocial and phys-
ical status and examining outcomes with quality of life
measures.
Stimulation trial as a reliable predictor for
long-term success
A successful temporary trial of stimulation has been
considered the best predictor of long-term outcome [35]
in different groups of chronic pain patients who are can-
didates for neuromodulation. However, a positive trial
does not guarantee long term success. The two largest,
multicenter, prospective trials of spinal cord stimulationfor the treatment of chronic pain after spine surgery re-
quired a positive trial as key inclusion criteria for pa-
tients enrollment [36,37]. Despite an high initial trial to
implant ratio (83% in both studies), successful outcome
at one year dropped dramatically (55% - 47%) [37,38].
There is no available literature on the ability of a
percutaneous trial to predict long-term benefit of ONS
implant [39]. Subgroup analysis of data coming from
one large RCT of ONS in CM showed that patients
who positively responded during a percutaneous trial
before the permanent implant reported a decrease in
headache days per month significantly greater than
those who failed the trial [16]. However, only short
term data was published so we do not know if the
successful trial predicted long-term benefit. Moreover,
we do not know if a longer period of stimulation in
those who failed the trial might have resulted in benefit
in the longer term. In our series of patients, despite an
initial trial success rate of 88%, 7/23 systems were
removed due to inefficacy, and only nine subjects (53%)
with a diagnosis of chronic migraine reported signifi-
cant pain relief (>50% relief in attacks’ intensity and/or
frequency) after an average follow-up of 40 months. A
retrospective review of ONS in heterogeneous head-
ache patient population has been recently published
reporting similar data in terms of trial success rate
(89%), system efficacy (56%), and long-term benefit in
CM patients (42% at an average of 34 months) [40].
Rarely ONS-induced improvements are evident within
days, as the neuromodulatory processes involved are
believed to occur slowly in different areas of the whole
nociceptive system [10]. The reported benefit of a short
(7 – 10 days) percutaneous trial might represent a
placebo effect in a cohort of subjects who usually have
unrealistic expectations on the surgery, after having
failed most of the available treatments. The view of the
International Headache Society Clinical Trials Subcom-
mittee is that the subjective nature of migraine features
and a high placebo effect invalidate open and single-
blind trials of any prophylactic intervention and that
the number of migraine attacks and number of migraine
days should be collected prospectively for an interval of
time long enough to be compared with a prospective
baseline of at least 1 month [41]. A one or two weeks
percutaneous ONS trial will not satisfy this standard.
Furthermore, when a one-month, semi-permanent, tun-
nelled trial was employed to test ONS system efficacy
before implantation, the long-term outcome in CM pa-
tients was still only 47%, despite an accurate evaluation
of trial outcomes through specific pain questionnaires [26].
Therefore, the use of a trial test of ONS is now highly
questionable. Its ability to select long-term responders
appears poor and with >80% of patients going on to full
implantation anyway, a trial poses additional risk and
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the health care system.
Long-term treatment efficacy
Neuromodulation is an invasive and expensive treatment,
and should be reserved for specific subset of chronic
pain patients following evidence-based guidelines [42].
350 patients have been enrolled in three large, industry
sponsored, randomized control trials in the efforts to
evaluate safety and efficacy of ONS to treat rCM
[12,13,16]. Two found no significant support for an ad-
equate therapeutic effect (responders defined as 50%
reduction in headache days per month), and the other
found only a moderate benefit (responders defined as
30% improvement in pain) in 39% of the treated subjects.
Different study designs, with controversial end-point
choices, do not allow a direct comparison of the trials’
results. Furthermore, no conclusions on long-term treat-
ment efficacy can be drawn as only 3 months follow/up
data have been reported to date. In our patients the
average time of system removals for inefficacy is around
23 months (range 2 – 54).
An analysis of the available ONS literature reported
long-term implant response rate is high (88% to 100%)
when peripheral stimulation is performed to elicit pa-
resthesia in the whole painful area, compared to a low
response rate (40%) in those studies reporting non-
concordant paresthesia [43]. Some authors hypothe-
sized that the combined stimulation of areas innervated
by both the occipital nerves (ON) and supraorbital
nerves (SON) might benefit those patients who per-
ceived pain in a hemicephalic or global extent [43,44].
Interestingly, in our series we found no differences among
the patients who reported Excellent/Good paresthesia
in terms of long-term positive outcome (64% vs 66%),
and 4 out of 5 patients with migraine origin in the tri-
geminal area had good long-term outcome. Moreover
two patients had a supraorbital lead added later on in
the attempt of increase paresthesia coverage and system
efficacy, but only one of them reported significant
benefit. As adding supraorbital leads increases surgical
times and complexity, a carefully designed trial is war-
ranted to establish the long-term benefit of this new
approach.
Hardware-related complications
Currently available ONS technology, originally designed
for epidural use, is associated with troublesome compli-
cations when used subcutaneously for ONS. Skin ero-
sion, lead breakage, lead migration, and pain around the
battery site can occur. These are not only direct adverse
events for the patient, but also impact on ONS efficacy,
and dramatically increase health care expenditure as
further surgical procedures and new equipment areoften required. In our series, almost 43% of the patients
required at least one surgical revision to treat such
problems. In 90% of cases leads or the intermediate
connections were the culprit. Similar numbers have
been reported in another recent retrospective review of
ONS in heterogeneous headache patient population,
with 58% of patients needing a surgical revision [40]. In
the larger RCTs, where only 3 months data have been
disclosed, surgical revision rates were already between
19% [13] and 37% [12].
Lead migration and lead breakage, major causes of
ONS-related surgical revision, are related to repeated
lead and extension traction events due to the high mo-
bility of the implanted area. Over the years, some authors
have described techniques to minimize these complica-
tions. Bennett suggested securing each lead ipsilaterally
to the lateral pocket fascia using 2 suture sleeves sepa-
rated by a strain relief loop, and anchoring each sleeve
to the fascia with 3 sutures and intraluminal medical
adhesive [16]. Franzini et al. recommend securing the
distal end of the lead to the lateral portion of the super-
ficial cervical fascia (with two additional skin incisions)
to prevent lead migration and report no displacement
at 1 year follow-up in 17 patients [45]. Additional strain
relief loops are recommended at the upper thoracic level
(T2- T4), at the implantable pulse generator (IPG), and
at any other incisions [16]. Finally, IPG implantation
sites other than the traditional gluteal region may have
the advantage of less pathway length change during pa-
tient movement. Thus, infraclavicular and low abdomen
IPG sites may result in less lead migration/rupture [46].
This literature reveals that specialist expertise by the
neuromodulator is important factor in outcome.
Limitations
Our audit has several weaknesses. Its design is flawed
by the well-known limitations of retrospective case-series
studies [47]. Lead/anchor technology and our surgical
technique have evolved so some of the problems we
have highlighted are already being addressed. Different
measures were collected over the years, and our choice of
using patients’ subjective report of headache’s intensity/
frequency reduction to define long-term success is not
highly robust. Any prospective trial should now endorse
the outcome measures defined by Task Force of the Inter-
national Headache Society Clinical Trials Subcommittee
[41]. Finally, we couldn’t collect enough information to
report and comment on medication-overuse headache.
Conclusions
Our audited series of 25 patients treated with ONS in
two tertiary neuromodulation centers is consistent with
literature suggesting that ONS is a therapeutic option
for patients with refractory chronic migraine (9 of 17
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and or intensity at long-term follow up), and refractory
occipital neuralgia (all patients reporting >50% reduction
in pain frequency and or intensity at long-term follow up).
There is a need to refine patient selection for ONS
and ensure optimal medical, psychological and surgical
management at all stages - a multidisciplinary team com-
prising of headache, psychology, and neuromodulation
specialists is essential for this. Such teams should be used
in future randomized controlled trials with long-term
follow-up to further determine the place for ONS in re-
fractory chronic headache management and improve
patient outcomes.
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